论文部分内容阅读
目的观察美罗华联合米托蒽醌治疗恶性淋巴瘤的临床疗效。方法将60例恶性淋巴瘤患者,随机分为米托蒽醌组(29例)与美罗华联合米托蒽醌组(31例)。米托蒽醌组采用米托蒽醌、依托泊苷和地塞米松治疗,美罗华联合米托蒽醌组在前者治疗的基础上加用美罗华治疗。60例患者化疗4个周期后进行疗效评价,随访观察生存情况。结果米托蒽醌组CR为68.1%;美罗华联合米托蒽醌组CR为87.3%,两组CR率比较,有显著性差异(P<0.05)。米托蒽醌组1年总生存率(OS)为87.8%,2年OS为76.8%,3年OS为75.4%;美罗华联合米托蒽醌组为91.6%,2年OS为81.6%。3年OS为78.7%;两组1、2、3年OS比较均有显著性差异(P均<0.05)。结论美罗华联合米托蒽醌治疗恶性淋巴瘤的疗效显著,值得在临床中大力开展。
Objective To observe the clinical efficacy of rituximab combined with mitoxantrone in the treatment of malignant lymphoma. Methods Sixty patients with malignant lymphoma were randomly divided into mitoxantrone group (n = 29) and rituximab plus mitoxantrone group (n = 31). The mitoxantrone group was treated with mitoxantrone, etoposide and dexamethasone, and the combination of rituximab and mitoxantrone was treated with rituximab on the basis of the former. Sixty patients were evaluated after 4 cycles of chemotherapy, and the survival was observed. Results The mitoxantrone group CR was 68.1%. The rituximab combined with mitoxantrone group CR was 87.3%. There was significant difference (P <0.05) between two groups. The 1-year overall survival (OS) was 87.8% for the mitoxantrone group, 76.8% for the 2-year OS, 75.4% for the 3-year OS, 91.6% for the rituximab plus mitoxantrone group, and 81.6% for the 2-year OS. The 3-year OS was 78.7%. There was a significant difference in OS between the two groups at 1, 2 and 3 years (all P <0.05). Conclusion The combination of rituximab and mitoxantrone is effective in the treatment of malignant lymphoma and deserves to be carried out clinically.